[Predictors of thromboembolic complications in patients with severe SARS-CoV-2 coronavirus infection].

Autor:	Podzolkov VI; Sechenov First Moscow State Medical University (Sechenov University)., Volchkova EV; Sechenov First Moscow State Medical University (Sechenov University)., Tarzimanova AI; Sechenov First Moscow State Medical University (Sechenov University)., Bragina AE; Sechenov First Moscow State Medical University (Sechenov University)., Ivannikov AA; Sechenov First Moscow State Medical University (Sechenov University)., Bykova EE; Sechenov First Moscow State Medical University (Sechenov University)., Shvedov II; Sechenov First Moscow State Medical University (Sechenov University)., Oganesyan KA; Sechenov First Moscow State Medical University (Sechenov University)., Isaeva AY; Sechenov First Moscow State Medical University (Sechenov University).
Jazyk:	ruština
Zdroj:	Terapevticheskii arkhiv [Ter Arkh] 2023 Dec 22; Vol. 95 (11), pp. 907-912. Date of Electronic Publication: 2023 Dec 22.
DOI:	10.26442/00403660.2023.11.202472
Abstrakt:	Aim: To identify predictors of the development of thromboembolic complications (TECs) in patients with severe SARS-CoV-2 coronavirus infection. Materials and Methods: A single-center observational retrospective study included 1634 patients with a confirmed diagnosis of SARS-CoV-2 coronavirus infection. The patients were divided into 2 groups depending on the availability of the feasibility study. The criterion for inclusion of patients in the main group was the presence of venous feasibility studies in 127 patients (group I), the comparison group consisted of 1507 patients in whom the course of COVID-19 was not complicated by the development of feasibility studies (group II). Results: When performing computed tomography of the chest organs, it was revealed that patients with a feasibility study had a higher percentage of lung tissue damage than patients in the comparison group: 55% [37.5; 67.5] and 37.5% [25.0; 47.5], respectively (p<0.001). The average values of C-reactive protein in I patients group were 129 [60.1; 211] ng/l, which was significantly higher than in II patients group - 41.0 [12.2; 97.6] ng/l (p<0.001), interleukin-6 - 176 [52.9; 471] pg/ml and 39.4 [11.0; 107] pg/ml (p<0.001), respectively. A one-factor regression analysis proved a significant contribution of comorbid pathology to the development of feasibility studies in patients with COVID-19. The presence of three nosologies at the same time: arterial hypertension, coronary heart disease (CHD) and chronic kidney disease increased the probability of a feasibility study by 4.81 times (odds ratio 4.8117, 95% confidence interval 3.2064-7.2207), in patients with arterial hypertension, CHD, chronic kidney disease and type 2 diabetes - by 5.63 times (odds ratio 5.6321, 95% confidence interval 3.1870-9.9531). Conclusion: The presence of severe comorbid pathology significantly increased the risk of developing a feasibility study in patients with COVID-19. The most significant predictors of the development of feasibility studies in patients with severe SARS-CoV-2 coronavirus infection. They are: CHD, arterial hypertension and type 2 diabetes.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu